[Pharmacology of misoprostol (pharmacokinetic data, adverse effects and teratogenic effects)].
Misoprostol is a synthetic analogue of prostaglandin E1. It is used in gynaecology because of its properties of myometrium smooth muscle cells contraction and its effects on the cervix. Misoprostol oral bioavailability is low and several authors have assessed whether the administration by other routes increased its pharmacodynamic effects. This paper summarizes the pharmacokinetic studies after other routes of administration: vaginal, sublingual, buccal or rectal. It also provides an update on its adverse effects and teratogenic effects.
Service de pharmacologie clinique, centre régional de pharmacovigilance, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex, France.
J
J
Aubert
Service de pharmacologie clinique, centre régional de pharmacovigilance, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex, France.
T
T
Bejan-Angoulvant
Service de pharmacologie clinique, centre régional de pharmacovigilance, CHRU de Tours, 2, boulevard Tonnellé, 37044 Tours cedex, France. Electronic address: jonville-bera@chu-tours.fr.
A-P
AP
Jonville-Bera
D000014:Abnormalities, Drug-Induced / Q000209:etiology*; D000020:Abortifacient Agents, Nonsteroidal; D000028:Abortion, Induced; D000278:Administration, Buccal; D000282:Administration, Intravaginal; D000285:Administration, Rectal; D000286:Administration, Sublingual; D020070:Cervical Ripening; D002584:Cervix Uteri / Q000187:drug effects; D005260:Female; D006801:Humans; D016595:Misoprostol / Q000008:administration & dosage / Q000009:adverse effects* / Q000493:pharmacokinetics*; D010120:Oxytocics; D011247:Pregnancy; D014590:Uterine Contraction; D014599:Uterus / Q000187:drug effects
D000020:Abortifacient Agents, Nonsteroidal; D010120:Oxytocics; D016595:Misoprostol
Grossesse; Misoprostol; Pharmacocinétique; Pharmacokinectics; Pharmacologie; Pharmacology; Pregnancy; Review; Revue